Amsterdam, Netherlands – 26 Aug 2023: Ferric carboxymaltose (FCM) did not improve a hierarchical outcome of death, heart failure hospitalisations and exercise function in ambulatory patients with ...

Please provide your email address to receive an email when new articles are posted on . Among individuals with HF with reduced ejection fraction and iron deficiency who were implanted with a cardiac ...

According to a recent market assessment conducted by Future Market Insights, the global Intravenous Iron Drugs Market Size is predicted to reach US$ 6.3 billion by 2032. According to the report’s ...

The intravenous infusion of ferric carboxymaltose in patients with chronic HF and iron deficiency led to improved health status and NYHA functional class, study results suggested. Researchers for the ...

First and only high-dose intravenous iron for iron deficiency anemia of various etiologies SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a ...

Intravenous (IV) administration of ferric carboxymaltose can treat iron deficiency in non-dialysis-dependent CKD (ND-CKD) patients more effectively than oral iron preparations and it is better ...

Ferric carboxymaltose given as an IV bolus push injection is well tolerated and effective in correcting hemoglobin levels in hemodialysis patients with iron-deficiency anemia. Nearly 62% of patients ...

Trials such as HEART-FID and AFFIRM-AHF have demonstrated positive treatment results for injectable ferric carboxymaltose in patients with heart failure and iron deficiency. On June 5, 2023, the FDA ...

About The Study: In patients with heart failure and iron deficiency, ferric carboxymaltose did not significantly reduce the time to first heart failure hospitalization or cardiovascular death in the ...

Global Intravenous Iron Drugs Market was valued at US$ 2.6 Bn in 2021 and is expected to reach US$ 6.3 Bn by 2032, finds FMI in a recent market survey. As per the findings of the report, Intravenous ...